Novo Nordisk Shares Rise 4% Amid Positive Wegovy Pill Launch Data

Novo Nordisk shares jumped 4% to levels last seen in October after early US prescription data for its Wegovy weight-loss pill showed a solid launch. The oral version of Wegovy became available to US patients earlier this month, and analysts say the early data is supportive. The stock move came as rival Eli Lilly shares slid 4%. Novo is counting on Wegovy to broaden its patient base and improve growth visibility.